Humana exiting ACA exchanges, individual market in 2018

Humana will be leaving all Affordable Care Act (ACA) exchanges and withdraw all its business from the individual insurance market in 2018, becoming the first major insurer to make a full exit amid uncertainty about the law’s future.

The Feb. 14 announcement came hours after Aetna announced it had mutually ended plans to acquire Humana for $37 billion, a deal that was blocked by a federal judge on antitrust grounds. Humana will receive a $1 billion break-up fee ($630 million after taxes) as a result.

Regarding its marketplace business, Humana said it’s tried several strategies to make exchange plans profitable, including raising premiums, narrowing networks and reducing the number of areas it offered coverage. It claimed none of it has worked.

“All of these actions were taken with the expectation that the company’s Individual Commercial business would stabilize to the point where the company could continue to participate in the program. However, based on its initial analysis of data associated with the company’s healthcare exchange membership following the 2017 open enrollment period, Humana is seeing further signs of an unbalanced risk pool. Therefore, the company has decided that it cannot continue to offer this coverage for 2018,” Humana said.

The insurer had already scaled back its 2017 offerings to 156 counties in 11 states (Florida, Georgia, Illinois, Kentucky, Louisiana, Michigan, Missouri, Mississippi, Ohio, Tennessee and Texas). All of those states utilize the federally-facilitated marketplace, where enrollment did drop in the open enrollment period which ended Jan. 31. The company had about 201,000 customers in individual health plans as of January, including 152,000 in ACA-compliant plans, down from 654,800 individual market customers in 2016.

The most affected areas would be 19 counties in Tennessee where Humana was the only exchange insurer for 2017. There’s no provision in the law to guarantee coverage if no insurer wishes to participate in a given market. Another 60 counties would have only one participating insurer, assuming no other company enters or exits those markets.

President Donald Trump pointed to the exit to bolster his argument to repeal the law, tweeting “Obamacare continues to fail.”

Cynthia Cox, associate director of the Kaiser Family Foundation, said more insurers could follow Humana unless plans for the exchanges and the ACA as a whole are made clear before they have to start submitting plans for regulatory approval in the spring.

“With congressional efforts to repeal the law and HHS Secretary Tom Price's likely administrative changes, insurers face a great deal of uncertainty going into 2018," she said to POLITICO.

Humana does plan to maintain its presence in the group market, as well as continue to offer dental and vision plans. Its long-term strategy is to focus on its Medicare Advantage business and “enhancing” its care delivery strategy, including a greater use of risk-based arrangements.

“As the company’s business model demonstrates, when Humana integrates care with doctors and other healthcare professionals and serves members outside of traditional institutions, its members’ health improves, care is more cost-effective, and consumers are more engaged. These are key drivers to enabling more affordable healthcare for consumers and facilitating higher Star quality ratings, while also improving financial performance,” the company said. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.